prevent blood clots from forming, do not break down clots
used to treat VTE
used in ACS to prevent cardioembolic stroke
anticoagulants
3 factors that can lead to activation of coagulation (Virchows triad)
blood vessel injury, blood stasis, pro-thrombotic conditions
DTIs (argatroban, bivalrudin, dabigatran) act on
thrombin, IIa
inhibitors of factor Xa include
direct - rivaroxaban, apixaban, edoxaban
indirect- fondaparinux
which factors are targeted by heparins
Xa, IIa
which factors are targeted by warfarin
VII, IX, X, II
DOACs include
direct Xa inhibitors and DTIs
vitamin K antagonist that blocks use of K for activation of factors _ _ _ _?
II, VII, IX, X
warfarin
warfarin has a narrow therapeutic index and requires monitoring of
INR
when is warfarin preferred over DOAC for stroke prevention in AF
mod-to-sev mitral stenosis or a mechanical heart valve
when is warfarin preferred over DOAC for VTE treatment
triple positive antiphospholipid syndrome or a mechanical heart valve
Beers List consideration for DOACs
rivaroxaban has increased bleeding risk and should be avoided for long term use of AF/VTE in older adults
endogenous anticoagulant that inactivates thrombus and factor Xa
antithrombin (AT)
which anticoagulants bind antithrombin to increase its activity
UFH, LWMHs, fondaparinux
which heparin inhibits factor Xa more greatly
LMWH»_space; UFH
anticoagulants are high alert medications since they
have risk of significant bleeding
check for acute Hg drop
binds antithrombin and inactivates thrombin (IIa) and Xa preventing conversion of fibrinogen to fibrin
UFH
dose of UFH used for VTE prophylaxis
5000 units SC Q8-12H
dose of UFH used for treatment of VTE
80 units/kg IV bolus
18 units/kg/hr infusion
dose of UFH used for treatment of ACS/NSTEMI
60 units/kg IV bolus
12 units/kg/hr infusion
what weight is used for UFH dosing
total body weight
warnings and contraindication of UFH
CI - active bleed
warning - fatal med errors, verify correct concentration
AEs of UFH
bleeding, thrombocytopenia, HIT, hyperkalemia
how to monitor UFH?
what is the therapeutic range of aPTT?
target aPTT or anti-Xa levels - check 6 hrs after initiation then every 6 hours until therapeutic
aPTT therapeutic range is 1.5-2.5x control
monitoring not required for SC dosing
PLT, H&H